
Sign up to save your podcasts
Or


Send us a text
Manal Abdelmalek, Naim Alkhouri, and Akero Therapeutics Chief Development Officer Kitty Yale join the Surfers to discuss Friday's FDA webcast on NASH Drug Development.
Friday's FDA Webcast on NASH drug development provided few concrete answers but several clues and directions to pursue. Listen as Manal Abdelmalek, Naim Alkhouri, and Kitty Yale, Chief Development Officer at Akero Therapeutics, join the Surfers to read the tea leaves and identify fruitful areas for further research and pursuit. Issues around diagnostics and the risk: benefit tradeoff received particular attention.
By SurfingNASH.com3.9
2424 ratings
Send us a text
Manal Abdelmalek, Naim Alkhouri, and Akero Therapeutics Chief Development Officer Kitty Yale join the Surfers to discuss Friday's FDA webcast on NASH Drug Development.
Friday's FDA Webcast on NASH drug development provided few concrete answers but several clues and directions to pursue. Listen as Manal Abdelmalek, Naim Alkhouri, and Kitty Yale, Chief Development Officer at Akero Therapeutics, join the Surfers to read the tea leaves and identify fruitful areas for further research and pursuit. Issues around diagnostics and the risk: benefit tradeoff received particular attention.

32,304 Listeners

30,807 Listeners

9,749 Listeners

104 Listeners

21,250 Listeners

3,375 Listeners

113,521 Listeners

57,033 Listeners

9,577 Listeners

8,704 Listeners

10,275 Listeners

6,470 Listeners

0 Listeners

419 Listeners

683 Listeners